On October 10, TestingCatalog noticed that an unannounced model, gpt-rosalind-discovery, had quietly appeared on OpenAI's API pricing page under “Life Sciences Models”, priced identically to gpt-rosalind-research.
A team at the First Affiliated Hospital of Nanjing Medical University reports in the Journal of Translational Medicine that the RFdiffusion protein design system generated a CLDN18.2-targeting T-cell engager from scratch, offering a new approach to gastric cancer immunotherapy.
A team combined AI protein structure prediction with high-throughput proteomics to discover molecular-glue degraders that target VAV1, a key immune-signaling protein, as reported by Hanfeng Lin et al. in Nature Communications in 2026.
A team at LMU Munich has developed SPARCS, which uses AI to analyze microscope images of 70 million cells at once and systematically screen how gene changes affect cells, as reported in Cell on October 8, 2026.
Anthropic says its Claude model helped discover a new enzyme system in bacteriophages, array-associated reverse transcriptases (ART), which feature CRISPR-like repeat arrays; 950 agents found it in 21 hours.
Illumina released SpliceAI2 on October 8, a genomic AI model that predicts how genetic variants alter RNA splicing, a key step in interpreting variants of uncertain significance.
AI-native pharmaceutical company Talus Bio has launched Ptarmigan-1, billed as the first AI model that can predict small-molecule binding across the entire human proteome without needing three-dimensional structures, and has opened public access.